{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:20:13Z","timestamp":1763018413767,"version":"build-2065373602"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.hfc.2021.07.008","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T08:47:57Z","timestamp":1634892477000},"page":"177-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia"],"prefix":"10.1016","volume":"18","author":[{"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Fimiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Moscarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Akioyamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"D\u2019Erasmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.hfc.2021.07.008_bib1","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.008_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype\u2013phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.008_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000179","article-title":"Homozygous autosomal dominant hypercholesterolaemia","volume":"26","author":"Sjouke","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.hfc.2021.07.008_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2020.08.027","article-title":"Homozygous familial hypercholesterolemia in Italy: clinical and molecular features","volume":"312","author":"Bertolini","year":"2020","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacc.2017.11.028","article-title":"Autosomal recessive hypercholesterolemia","volume":"71","author":"D\u2019Erasmo","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.008_bib8","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2007.00915.x","article-title":"Genetic heterogeneity of autosomal dominant hypercholesterolemia","volume":"73","author":"Varret","year":"2007","journal-title":"Clin Genet"},{"issue":"19","key":"10.1016\/j.hfc.2021.07.008_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The Severe hypercholesterolemia phenotype","volume":"63","author":"Sniderman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2021.07.008_bib11","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.hfc.2021.07.008_bib12","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.008_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0000000000000686","article-title":"Evidence for improved survival with treatment of homozygous familial hypercholesterolemia","volume":"31","author":"B\u00e9langer","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(99)00435-9","article-title":"Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia","volume":"150","author":"Raal","year":"2000","journal-title":"Atherosclerosis"},{"issue":"5661","key":"10.1016\/j.hfc.2021.07.008_bib15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.hfc.2021.07.008_bib16","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hfc.2021.07.008_bib17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib18","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.atherosclerosis.2006.10.036","article-title":"Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients","volume":"194","author":"Pisciotta","year":"2007","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.hfc.2021.07.008_bib19","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.008_bib21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients","volume":"5","author":"Goldberg","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"S1","key":"10.1016\/j.hfc.2021.07.008_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11789-012-0049-3","article-title":"Role of lipid apheresis in changing times","volume":"7","author":"Schuff-Werner","year":"2012","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.hfc.2021.07.008_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2018.01.012","article-title":"Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies","volume":"269","author":"Gragnano","year":"2018","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib25","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1111\/j.1399-3046.2010.01383.x","article-title":"Preemptive liver transplantation in a child with familial hypercholesterolemia","volume":"15","author":"Maiorana","year":"2011","journal-title":"Pediatr Transplant"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12265-011-9311-1","article-title":"Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively","volume":"5","author":"Ibrahim","year":"2012","journal-title":"J\u00a0Cardiovasc Transl Res"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1399-3046.2010.01469.x","article-title":"Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia","volume":"15","author":"Tevfik","year":"2011","journal-title":"Pediatr Transplant"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1399-3046.2010.01458.x","article-title":"Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late","volume":"15","author":"Malatack","year":"2011","journal-title":"Pediatr Transplant"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib29","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12967-019-2123-9","article-title":"Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy","volume":"17","author":"Cao","year":"2019","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.hfc.2021.07.008_bib31","first-page":"11","article-title":"PCSK9 variants in familial hypercholesterolemia: a comprehensive synopsis","author":"Guo","year":"2020","journal-title":"Front Genet"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.008_bib32","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition","volume":"46","author":"Cesaro","year":"2020","journal-title":"Biofactors"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2459\/JCM.0000000000000611","article-title":"Adherence to proprotein convertase subtilisin\/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience","volume":"19","author":"Gragnano","year":"2018","journal-title":"J\u00a0Cardiovasc Med"},{"key":"10.1016\/j.hfc.2021.07.008_bib35","first-page":"4","article-title":"Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk","author":"Cesaro","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2021.07.008_bib36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hfc.2021.07.008_bib37","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hfc.2021.07.008_bib38","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMc1712102","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Calabr\u00f2","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9965","key":"10.1016\/j.hfc.2021.07.008_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2459\/JCM.0000000000001077","article-title":"Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies","volume":"22","author":"Cesaro","year":"2021","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.008_bib41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.008_bib42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia","volume":"76","author":"Blom","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A\u00a0highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13543784.2018.1442435","article-title":"Inclisiran for the treatment of dyslipidemia","volume":"27","author":"Nishikido","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"10.1016\/j.hfc.2021.07.008_bib46","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.119.044431","article-title":"Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin\/kexin type 9 expression in homozygous familial hypercholesterolemia","volume":"141","author":"Hovingh","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-7075-9-14","article-title":"Multiple functions of microsomal triglyceride transfer protein","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr Metab (Lond)"},{"issue":"9860","key":"10.1016\/j.hfc.2021.07.008_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.008_bib49","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy","volume":"34","author":"D\u2019Erasmo","year":"2017","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2459\/JCM.0000000000000620","article-title":"Lomitapide in homozygous familial hypercholesterolemia","volume":"19","author":"Sperlongano","year":"2018","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"17","key":"10.1016\/j.hfc.2021.07.008_bib51","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/2047487317730473","article-title":"The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis","volume":"24","author":"Leipold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.008_bib52","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","article-title":"Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B","volume":"76","author":"Crooke","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"9719","key":"10.1016\/j.hfc.2021.07.008_bib54","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.008_bib55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrendo.2017.119","article-title":"Angiopoietin-like 3 in lipoprotein metabolism","volume":"13","author":"Kersten","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.008_bib56","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.008_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOL.0000000000000668","article-title":"Familial combined hypolipidemia","volume":"31","author":"Arca","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/clp.12.92","article-title":"Familial combined hypolipidemia due to mutations in the ANGPTL3 gene","volume":"8","author":"Calandra","year":"2013","journal-title":"Clin Lipidol"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.008_bib59","doi-asserted-by":"crossref","first-page":"158679","DOI":"10.1016\/j.bbalip.2020.158679","article-title":"ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins","volume":"1865","author":"Ruhanen","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.008_bib60","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1194\/jlr.P039875","article-title":"Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis","volume":"54","author":"Minicocci","year":"2013","journal-title":"J\u00a0Lipid Res"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.008_bib61","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J\u00a0Lipid Res"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.008_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.008_bib63","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.amjcard.2019.09.010","article-title":"Usefulness of gemcabene in homozygous familial hypercholesterolemia (from COBALT-1)","volume":"124","author":"Gaudet","year":"2019","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2021.07.008_bib64","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A\u00a0pilot study of ex\u00a0vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.008_bib65","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jgm.554","article-title":"Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia","volume":"6","author":"Lebherz","year":"2004","journal-title":"J\u00a0Gene Med"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.008_bib66","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.008_bib67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In\u00a0vivo AAV-CRISPR\/Cas9\u2013mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.008_bib69","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1038\/s41598-019-41056-w","article-title":"Function and immunogenicity of gene-corrected iPSC-derived hepatocyte-like cells in restoring low density lipoprotein uptake in homozygous familial hypercholesterolemia","volume":"9","author":"Okada","year":"2019","journal-title":"Sci Rep"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:43:11Z","timestamp":1761554591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713621000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1551713621000775"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2021.07.008","relation":{},"ISSN":["1551-7136"],"issn-type":[{"type":"print","value":"1551-7136"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2021.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}